ASX Share rice
Sun 16 May 2021 - 07:06:am (Sydney)

PAA Share Price

PHARMAUST LIMITEDPAAPharmaceuticals, Biotechnology & Life Sciences

PAA Company Information

Name:

PharmAust Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

5/3 Brodie Hall Drive Bentley WA Australia 6102

Phone:

61 8 9202 6814

Exec. Chairman & Acting CEO:

Dr. Roger Aston B.Sc., BSc (Hons), Ph.D.

Fin. Director, Company Sec. & Director:

Mr. Sam Michael Wright A.C.I.S., M.A.I.C.D., AFin, DipAcc, ACIS, MAICD

Chief Scientific Officer:

Dr. Richard Mollard

Exec. Director:

Mr. Robert Charles Bishop

Chief Exec. Officer of Epichem Pty Ltd:

Mr. Colin La Galia

Director of Epichem Pty Ltd:

Ms. Rebecca McCrackan

Company Overview:

PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

PAA Share Price Information

Shares Issued:

316.73M

Market Capitalisation:

$30.41M

Revenue (TTM):

$3.44M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.007

Profit Margin:

-0.4963

Operating Margin (TTM):

$-0.46

Return On Assets (TTM):

$-0.09

Return On Equity (TTM):

$-0.18

Quarterly Revenue Growth (YOY):

-0.275

Gross Profit(TTM):

$3.87M

Diluted Earnings Per Share (TTM):

$-0.005

PAA CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-30,229

Change To Liabilities:

$-116,019

Total Cashflow From Investing Activities:

$-30,229

Net Borrowings:

$-294,025

Net Income:

$-1,361,990

Total Cash From Operating Activities:

$-1,270,002

Depreciation:

$274.64K

Change To Inventory:

$-245,753

Change To Account Receivables:

$-38,841

Sale Purchase Of Stock:

$2.38M

Capital Expenditures:

$30.23K

PAA Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-1,361,990

Net Income:

$-1,361,990

Gross Profit:

$3.88M

Operating Income:

$-1,243,500

Interest Expense:

$118.50K

Total Revenue:

$4.12M

Cost Of Revenue:

$246.16K

PAA Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$3.11M

Total Liabilities:

$2.22M

Total Stockholder Equity:

$8.53M

Total Assets:

$10.75M

Common Stock:

$53.77M

Other Current Assets:

$34.36K

Retained Earnings:

$-47,201,808

Other Liabilities:

$44.51K

Cash:

$2.88M

Total Current Liabilities:

$1.06M

Property - Plant & Equipment:

$3.57M

Net Tangible Assets:

$5.42M

Total Current Assets:

$4.07M

Long-Term Debt:

$38.21K

Net Receivables:

$310.65K

Short-Term Investments:

$6.68M

Inventory:

$857.57K

Accounts Payable:

$557K

Short-Term Investments:

$6.68

Non Current Liabilities Total:

$1.12M

PAA Share Price History

PAA News

10 Nov, 2020
Roger Aston became the CEO of PharmAust Limited (ASX:PAA) in 2018, and we think it's a good time to look at the...